Ziprasidone HydrochlorideThird Party Manufacturing in India

Ziprasidone Hydrochloride works by acting as an antagonist at D₂ dopamine and 5-HT₂A serotonin receptors, alongside high-affinity antagonism at 5-HT₁D and partial agonism at 5-HT₁A receptors. It modulates neurotransmitter balance in core cortical areas to help the body alleviate both positive and negative symptoms of schizophrenia. Unlike several alternative atypical antipsychotics, it features a lower incidence of causing significant weight gain or metabolic syndrome. It is highly effective and well-tolerated under appropriate cardiac monitoring.

Therapeutic Uses

• Schizophrenia: Indicated for the acute treatment and maintenance management of schizophrenia in adult patients.
• Bipolar I Disorder: Used as monotherapy or adjunctive treatment for acute manic or mixed episodes associated with bipolar disorder.

Why Manufacturers Choose Ziprasidone Hydrochloride

Ziprasidone Hydrochloride third party manufacturing in India offers an advantageous path for brands breaking into highly technical neuropsychiatry markets. Managing the synthesis and formulation of CAS 138982-67-9 requires precise physical control to achieve accurate bioequivalence profiles. Celesta Healthcare utilizes specialized partner networks whose production facilities are WHO-GMP certified, providing consistent dissolution and particle size attributes. These WHO-GMP validated resources help brand owners secure long-term clinical compliance and commercial success.